

# Screening S. aureus CRISPR-Cas9 Paired Guide RNAs for Efficient Targeted **Deletion in Duchenne Muscular Dystrophy**

Josh Tycko<sup>1</sup>, Nick Huston<sup>1</sup>, Jacqueline Robinson-Hamm<sup>2</sup>, Chris Wilson<sup>1</sup>, Charles A. Gersbach<sup>2</sup>, Patrick D. Hsu<sup>1</sup>, David Bumcrot<sup>1</sup> I. Editas Medicine, 300 Third St., Cambridge, MA 02142 2. Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708

#### Background

- Duchenne muscular dystrophy (DMD) is a X-linked recessive neuromuscular disorder that results in progressive muscle degeneration and premature death. Most patients have frameshifting mutations in the dystrophin gene that result in a nonfunctional protein.
- In contrast, Becker muscular dystrophy (BMD) patients generally have mutations in dystrophin that do not disrupt the reading frame, leading to a milder disease phenotype.
- Thus, CRISPR/Cas9 targeted deletions that restore the reading frame could convert DMD genotypes into BMD-like genotypes and potentially ameliorate the phenotype of this disease. The smaller Cas9 ortholog from S. aureus can be packaged with paired guide RNAs in an AAV vector for in vivo gene editing.

## **Experimental Overview**

- Deleting Exon 51 would restore the dystrophin reading frame for the greatest number of patients of any single exon deletion.
- From the set of 10,553 21-nt S.aureus Cas9 (SaCas9) guide RNAs targeting human DMD introns 50 and 51, we selected pairs that passed design filters intended to improve guide RNA expression, improve SaCas9 cleavage efficiency, and minimize off-target editing concerns.

## **Conclusions**

- Screening identified several candidate guide RNA pairs, including pairs with up to 25% deletion efficiency in DMD myoblasts.
- Lead guide RNAs mediate the precise desired deletion in immortalized DMD myoblasts.
- Deletion size plays a role in deletion efficiency, but is not highly predictive.







